What is the new nanoinjection platform developed by IIT Madras?

It's a novel drug delivery system using nanoarchaeosomes in silicon nanotubes to deliver doxorubicin directly into breast cancer cells.

How does the IIT Madras nanoinjection improve breast cancer treatment?

It targets cancer cells precisely, minimizing harm to healthy tissues and showing higher potency at lower doses, reducing side effects and costs.

What are the advantages of silicon nanotubes in cancer drug delivery?

Silicon nanotubes are biocompatible and non-toxic, making the nanoinjection platform more reliable and scalable for clinical use.

Home / Science / Breakthrough Nanoinjection Targets Breast Cancer

Breakthrough Nanoinjection Targets Breast Cancer

22 Dec

•

Summary

Nanoinjection system delivers doxorubicin directly into cancer cells.
Demonstrated 23 times lower inhibitory concentration than free doxorubicin.
Silicon nanotube base is biocompatible and non-toxic.

Breakthrough Nanoinjection Targets Breast Cancer

An international research team, spearheaded by IIT Madras, has engineered a pioneering nanoinjection platform designed to revolutionize breast cancer therapy. This advanced system employs nanoarchaeosomes within silicon nanotubes to deliver the chemotherapy drug doxorubicin directly into malignant cells. By doing so, it significantly enhances therapeutic efficacy while drastically reducing harm to surrounding healthy tissues. Initial studies in cell cultures and chick embryos showed remarkable success in eradicating cancer cells and inhibiting tumor growth.

The new platform, dubbed NAD-SiNTs, proved to be substantially more potent than free doxorubicin, requiring much lower doses. This translates to a potential reduction in treatment expenses and a decrease in adverse side effects for patients. The inherent biocompatibility and non-toxicity of the silicon nanotube base further simplify its application and enhance its suitability for widespread clinical use.